Consensus Allergen Vaccines for Multi-Allergen Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergy treatments, such as antihistamines and long-term allergen-specific immunotherapy (AIT), are inadequate for addressing multiple allergens due to their limited efficacy, duration, and side effects, leaving patients vulnerable to cross-reactivity among pollen and food allergens.
Innovation Solution
Development of synthetic and/or recombinant consensus allergens derived from aligned amino acid sequences of multiple protein allergens, designed to desensitize the immune system against multiple allergens simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional allergen-specific immunotherapy (AIT) is used to treat multiple allergens, then comprehensive coverage of different allergen types is achieved, but treatment complexity and time required increase significantly
Solution Approach 1:
The patent creates a universal allergen vaccine composition that can simultaneously target multiple allergen types (pollen, food, animal dander) through a single standardized protocol. The composition uses a limited set of recombinant allergen proteins that represent multiple allergen families, allowing one vaccine formulation to provide broad-spectrum protection without requiring separate personalized AIT programs for each allergen type.
Solution Approach 2:
The patent merges multiple allergen-specific treatments into a single combined vaccine composition. By selecting representative allergen proteins from different allergen families and combining them in a standardized formulation, the invention consolidates what would otherwise require multiple separate AIT treatments into one unified approach, reducing overall treatment complexity.
2Reliability
If long-term allergen-specific immunotherapy (3-5 years) is administered to achieve desensitization, then immune system desensitization is achieved, but treatment duration and patient burden increase
Solution Approach 1:
The patent employs preliminary action by using in silico prediction algorithms and epitope mapping before vaccine formulation. This pre-screening approach identifies the most immunogenic allergen proteins and critical epitopes in advance, allowing the vaccine to be optimized for maximum efficacy from the start. This preliminary computational analysis reduces the need for prolonged trial-and-error treatment periods by ensuring the vaccine contains the right allergen targets before administration begins.
Solution Approach 2:
The patent applies parameter changes by modifying allergen proteins through recombinant expression systems to enhance their immunogenicity and stability. By altering parameters such as protein purity, conformational structure, and epitope accessibility through recombinant technology, the vaccine achieves better immune response per dose, potentially reducing the total treatment duration required to reach desensitization compared to traditional extracts.
3Reliability
If multiple separate allergen treatments are provided to address cross-reactivity, then protection against cross-reactive allergens is improved, but number of treatments and administrative burden increase
Solution Approach 1:
The vaccine composition is designed with universal applicability across different allergen types by including recombinant proteins from major allergen families (pollen, food, animal dander). This multi-functional approach allows a single vaccine formulation to address cross-reactivity issues across multiple allergen categories simultaneously, eliminating the need for separate treatments for each allergen type while maintaining reliable protection.
Solution Approach 2:
The patent segments the complex problem of cross-reactive allergies into distinct allergen protein targets that can be individually selected and combined in the vaccine formulation. By identifying and isolating specific recombinant allergen proteins and their critical epitopes through computational segmentation, the vaccine can systematically address cross-reactivity patterns without requiring exhaustive treatment of all possible allergen combinations.
Data Source
AI summary
The present invention relates to synthetic and/or recombinant consensus allergens and to their use as allergy vaccines in particular in the treatment of peach-cypress allergy, in the form of an allergy vaccine comprising a consensus allergen and/or a nucleic acid sequence encoding such, wherein the consensus allergen comprises at least (60) amino acids and is derived from a consensus sequence of the amino acid sequences of at least five (5) protein allergens, and wherein said protein allergens share at least 20% amino acid sequence identity.